ZA200304404B - Genetic test for the identification of carriers of complex vertebral malformations in cattle. - Google Patents
Genetic test for the identification of carriers of complex vertebral malformations in cattle. Download PDFInfo
- Publication number
- ZA200304404B ZA200304404B ZA200304404A ZA200304404A ZA200304404B ZA 200304404 B ZA200304404 B ZA 200304404B ZA 200304404 A ZA200304404 A ZA 200304404A ZA 200304404 A ZA200304404 A ZA 200304404A ZA 200304404 B ZA200304404 B ZA 200304404B
- Authority
- ZA
- South Africa
- Prior art keywords
- seq
- marker
- bovine
- genetic
- microsatellite
- Prior art date
Links
- 241000283690 Bos taurus Species 0.000 title claims description 104
- 230000002068 genetic effect Effects 0.000 title claims description 62
- 230000036244 malformation Effects 0.000 title claims description 36
- 239000000969 carrier Substances 0.000 title description 20
- 238000012360 testing method Methods 0.000 title description 12
- 239000003550 marker Substances 0.000 claims description 70
- 108090000623 proteins and genes Proteins 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 51
- 238000012163 sequencing technique Methods 0.000 claims description 43
- 108091092878 Microsatellite Proteins 0.000 claims description 40
- 201000010099 disease Diseases 0.000 claims description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 210000000349 chromosome Anatomy 0.000 claims description 25
- 108700028369 Alleles Proteins 0.000 claims description 23
- 239000002773 nucleotide Substances 0.000 claims description 17
- 101100309387 Bos taurus SLC35A3 gene Proteins 0.000 claims description 16
- 239000002299 complementary DNA Substances 0.000 claims description 16
- 125000003729 nucleotide group Chemical group 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 12
- 230000003321 amplification Effects 0.000 claims description 11
- 238000007844 allele-specific PCR Methods 0.000 claims description 10
- 108091034117 Oligonucleotide Proteins 0.000 claims description 9
- 238000001514 detection method Methods 0.000 claims description 6
- 238000009007 Diagnostic Kit Methods 0.000 claims description 4
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 claims description 2
- 238000012175 pyrosequencing Methods 0.000 claims description 2
- 238000005096 rolling process Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 48
- 244000309466 calf Species 0.000 description 26
- 108020004414 DNA Proteins 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 18
- 102100033778 UDP-N-acetylglucosamine transporter Human genes 0.000 description 15
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 14
- 108091006542 SLC35A3 Proteins 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 230000035772 mutation Effects 0.000 description 12
- 244000309464 bull Species 0.000 description 11
- 241000282414 Homo sapiens Species 0.000 description 10
- 102000054766 genetic haplotypes Human genes 0.000 description 9
- 230000002441 reversible effect Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 101150083863 Slc35a3 gene Proteins 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 210000003917 human chromosome Anatomy 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000009395 breeding Methods 0.000 description 5
- 230000001488 breeding effect Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000003205 genotyping method Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- 108010070047 Notch Receptors Proteins 0.000 description 4
- 102000005650 Notch Receptors Human genes 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 230000009395 genetic defect Effects 0.000 description 4
- 244000309465 heifer Species 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 238000000059 patterning Methods 0.000 description 4
- 210000000582 semen Anatomy 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 206010010356 Congenital anomaly Diseases 0.000 description 3
- 101001138480 Homo sapiens Olfactory receptor 5AC2 Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 102100020806 Olfactory receptor 5AC2 Human genes 0.000 description 3
- 108010086873 UDP-N-acetylglucosamine transporter Proteins 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000005003 heart tissue Anatomy 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 239000011535 reaction buffer Substances 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000011218 segmentation Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000002023 somite Anatomy 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000007862 touchdown PCR Methods 0.000 description 3
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 208000008037 Arthrogryposis Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091033380 Coding strand Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101100309389 Homo sapiens SLC35A3 gene Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 238000009399 inbreeding Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- IOUNGFDUDUBFGX-UHFFFAOYSA-N n-(2-chlorophenyl)-2-[4-(2,4-dichlorophenyl)thiadiazol-5-yl]sulfanylacetamide Chemical compound ClC1=CC(Cl)=CC=C1C1=C(SCC(=O)NC=2C(=CC=CC=2)Cl)SN=N1 IOUNGFDUDUBFGX-UHFFFAOYSA-N 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 231100000272 reduced body weight Toxicity 0.000 description 2
- 206010039722 scoliosis Diseases 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 208000029761 vertebral disease Diseases 0.000 description 2
- 244000058084 Aegle marmelos Species 0.000 description 1
- 235000003930 Aegle marmelos Nutrition 0.000 description 1
- 206010003598 Atelectasis Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 108091060211 Expressed sequence tag Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- 102000051366 Glycosyltransferases Human genes 0.000 description 1
- 101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 101000860173 Myxococcus xanthus C-factor Proteins 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 102100023315 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Human genes 0.000 description 1
- 108010056664 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108010010677 Phosphodiesterase I Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 208000007123 Pulmonary Atelectasis Diseases 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 101710136739 Teichoic acid poly(glycerol phosphate) polymerase Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 210000002718 aborted fetus Anatomy 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 229940046545 animal allergen extract Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000025341 autosomal recessive disease Diseases 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 210000003797 carpal joint Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 208000010515 dystocia Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 231100000640 hair analysis Toxicity 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- -1 nucleotide sugars Chemical class 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 230000008775 paternal effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000011886 postmortem examination Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 210000000457 tarsus Anatomy 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 201000003130 ventricular septal defect Diseases 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
a
Genetic test for the identification of carriers of complex vertebral malformations . in cattle
The present invention relates generally to a genetic disease observed in bovines termed
Complex Vertebral Malformation (CVM). More particularly, the invention relates to mo- lecular markers for identifying potential bovine carriers of CVM and for identifying the CVM gene locus and mutations thereof responsible for complex vertebral malformation in bovines.
Complex Vertebral Malformation (CVM) is a congenital vertebral disorder detected in
Holstein-Friesian (HF) black and white dairy cattle. The disease has recently been de- scribed (Agerholm et al., 2000). In Denmark, all cases diagnosed until today (October 17, 2000) have been genetically related to the former elite US Holstein bull Carlin-M Ivanhoe
Bell. According to the present data, CVM appears to be inherited as an autosomal recessive disease.
The disease is characterised by a congenital bilateral symmetric arthrogryposis of the distal joints and malformations of the columna, mainly at the cervico-thoracic junction combined with reduced body weight (Agerholm et al., 1994).
Externally, there are the following major findings: In many cases the cervical and/or the thoracic part of the columna seems to be short. Moderate bilateral symmetric contraction of the carpal joints and severe contraction and supination of the phalango-metacarpal joint (fetlock) are constant findings. Contraction and pronation of the phalango-metatarsal joint and slight extension of the tarsus are also common findings. In most cases an irregular course of the columna around the cervico-thoracic junction is observed. Scoliosis may be observed, and lesions may be present in other regions of the columna. The irregular * 30 course is often recognised by inspection and palpation of the ventral aspect of the co- lumna. However, lesions may be minimal and restricted to two or few vertebrae. In such
R cases the columna may be of almost normal length. Therefore, radiological examination of the columna is recommended to exclude vertebral malformations in suspected cases. The spinal cord is of normal size lying with the vertebral canal without obvious compressions,
Using radiology, complex vertebral malformations consisting of hemivertebrae, fused and malshaped vertebrae, scoliosis, and anchylosis are found at varying degrees. This is best wala; Ja :
CONFIRMATICN COPY
~ WO 02/40709 PCT/DK01/00756 demonstrated following removal of the arcus vertebrae. In some cases malformations of the heart are present, mostly as a high interventricular septal defect and eccentric hyper- . trophy of the right ventricle. Malformations of the large vessels may occur. In the lungs fetal atelectasis is present. Serohemorrhagic fluids are most present in the thoracic cavity. } 5 A variety of other malformations have been observed, but these are not constant or com- mon findings. Lesions due to dystocia are often found.
Malformations have been observed both in aborted fetuses, prematurely born calves and in stillborn calves born at term. Cases among older calves have not yet been observed. In general the body weight is reduced, and the body weight is lower in premature born calves than in calves born at term.
Additionally, there seems to be an increased frequency of abortions in cows inseminated with semen of carrier bulis. At present the cause of this is unknown.
Presently, the only tool available for CVM diagnosis is patho-anatomical diagnosis based on the above described presence of bilateral symmetric arthrogryposis of the distal joints and malformations of the columna, mainly at the cervico-thoracic junction combined with reduced body weight. However, symmetric contractions of the limbs are common and general findings in vertebral malformations in calves. Therefore, differential diagnostic problems do exist as it is often difficult to differentiate between CVM and other malforma- tions.
The fact that the genetic defect appears to be spread by the bull Carflin-M Ivanhoe Bell which has been used intensively all over the world makes it of significant economic im- portance to be able to test whether current and potential breeding bulls are carriers of the defect.
In order to obtain an estimate of the frequency of potential CVM carrier animals within the
Danish cattle population, the present inventors have extracted pedigree information from the Danish national cattle database. At the time of the extraction (October 2000) there were registered 919,916 pure-bred cows and heifers, and 169,821 pure-bred bulls and . male calves. Bell was found 707,915 times in the pedigrees of the cows and heifers and 161,043 times in the male pedigrees. In Tables 1 and 2 below, the number of occurrences . 35 of Bell in each generation of the pedigrees is shown.
" 3
TABLE 1
Occurrence of Bell in the pedigrees of Danish Holstein cows and heifers " Cumulative
Generations NR Frequency Percent Frequency ee eee mee mm tm ee me ee mm em cen ) 2 21240 3.0 21244 3 202460 28.6 223704 4 321043 45.4 544747 5 133956 18.9 678703 6 27307 3.9 706010 7 1869 0.3 707879 8 36 0.0 707915
TABLE 2
Occurrence of Bell in the pedigrees of Danish Holstein bulls
Cumulative
Generation Frequency Percent Frequency 2 436 0.3 436 3 20144 12.5 20580 4 82394 51.2 102974 5 44545 27.7 147519 6 12455 7.7 159974 7 1040 0.6 161014 8 29 0.0 161043
Although these numbers also include some double and triple occurrences of Bell in the pedigrees, the data clearly show that a majority of the Danish Holstein cattle are potential carriers of CVM. Clearly, the problem is immense on a global scale.
Thus, there is great demand in the cattle industry for a genetic test that permits the identi- fication of cattle in various breeds that are potential carriers of CVM (e.g. before detectable onset of clinical symptoms).
Prior to the present invention, microsatellite mapping has not been applied to the gene causing the above complex vertebral malformations which has not been isolated or characterised. Thus, to the inventors’ best knowledge, the diagnostic method according to . the invention described in further detail in the following has not previously been suggested 40 or disclosed.
Accordingly, the present invention, which comprises mapping of the disease locus for Cup, has provided a DNA test based on microsatellite markers located on bovine chromosome
BTA3. The ability of the test to define the carrier status of animals descending from Be// 45 has been confirmed which appears from the examples below.
h WO 02/40709 PCT/DKO1/00756
Summary of the invention . In its broadest aspect, the present invention provides a method for detecting the presence in a bovine subject of a genetic marker associated with bovine complex vertebral malfor- mation (CVM), comprising the steps of providing a bovine genetic material, and detecting in the genetic material the presence or absence of at least one genetic marker that is linked to a bovine complex vertebral malformation disease trait or a specific nucleotide polymorphism which causes the complex vertebral malformation disease trait.
In a further aspect, the invention pertains to a diagnostic kit for use in detecting the pres- ence in a bovine subject of at least one genetic marker associated with bovine complex vertebral malformation (CVM), comprising at least one oligonucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ
ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID
NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15 , SEQ ID NO:16,
SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37 and SEQ 1D NO: 38, and combinations thereof. Furthermore, the invention relates to a diagnostic method including a diagnostic kit for the detection of a G/T polymorphism in the bovine
SLC35A3 gene causative and diagnostic for CVM in cattle.
One primary objective of the present invention is to enable the identification of cattle car- rying bovine complex vertebral malformation (CVM). This is achieved by a method which detects the presence of a genetic marker associated with bovine CMV in a bovine subject.
More specifically, the genetic marker may be the bovine SLC35A3 gene or even more specifically specific polymorphisms in the bovine SLC35A3 gene.
As used herein, the term a "bovine subject” refers to cattle of any breed. Thus, any of the various cow or ox species, whether male or female, are included in the term, and both adult and new-born animals are intended to be covered. The term does not denote a par- ticular age. One example of a bovine subject is a member of the Holstein-Friesian cattle population.
The term "genetic marker" refers to a variable nucleotide sequence (polymorphic) that is ) present in bovine genomic DNA on a chromosome and which is identifiable with specific oligonucleotides. Such a variable nucleotide sequence is e.g. distinguishable by nucleic acid amplification and observation of a difference in size or sequence of nucleotides due to the polymorphism. In useful embodiments, such genetic markers may be identified by several techniques known to those skilled in the art, and include typing of microsatellites or short tandem repeats (STR), restriction fragment length polymorphisms (RFLP), detection of deletion or insertion sites, and random amplified polymorphic DNA (RAPD) as well as the . typing of single nucleotide polymorphism (SNP) by methods including restriction-fragment- length polymerase chain reaction, allele-specific oligomer hybridisation, oligomer-specific ; 5 ligation assays, mini-sequencing, direct sequencing, fluorescence-detected 5’-exonuclease ‘ assays, and hybridisation with PNA and LNA probes and others. However, it will be appreciated that other genetic markers and techniques may be applied in accordance with the invention.
As described above, "bovine complex vertebral malformation” (CVM) is a congenital ver- tebral disorder. Presently, the disease has only been detected in Holstein-Friesian (HF) black and white dairy cattle; however, it is also contemplated that other bovine races may be affected. The disease has recently been described by Agerholm et al., 2000. Ac- cordingly, in the present context CV¥M and bovine complex vertebral malformation disease trait are to be understood as a disease resulting in the clinical symptoms previously described herein, and as reported and defined by Agerhoim et al., 2000.
The method according to the invention includes the provision of a bovine genetic material.
Such material include bovine DNA material which may be provided by any conventional method or means. The bovine DNA material may e.g. be extracted, isolated and purified from blood (e.qg., fresh or frozen), tissue samples (e.g., spleen, buccal smears), hair sam- ples containing follicular cells and semen.
As previously described, the method of the present invention further comprises a step of detecting in the genetic material the presence or absence of a genetic marker that is linked to a bovine complex vertebral maiformation disease trait.
In order to detect if the genetic marker is present in the genetic material, standard methods well known to persons skilled in the art may be applied, e.g. by the use of nucleic acid amplification. In order to determine if the genetic marker is genetically linked to the complex vertebral malformation disease trait, a lod score can be applied. A lod score, which is also sometimes referred to as Zyax, indicates the probability (the logarithm of the . ratio of the likelihood) that a genetic marker locus and a specific gene locus are linked at a particular distance. Lod scores may e.g. be calculated by applying a computer programme ] 35 such as the MLINK programme of the LINKAGE package (Lathrop et al., 1985). A lod score of greater than 3.0 is considered to be significant evidence for linkage between the genetic marker and the complex vertebral malformation disease trait or gene locus.
h WO 02/40709 PCT/DK01/00756
In one embodiment of the invention, the genetic marker is located on bovine chromosome
BTA3. The region of bovine chromosome BTA3 comprising the genetic markers that are . useful in the method of the present invention is indicated in Figure 2. . 5 Accordingly, genetic markers located on bovine chromosome BTA3 in the region flanked by and including the polymorphic microsatellite markers BM4129 and BMS1266, may be useful according to the present invention. In one specific embodiment, the at least one ge- netic marker is located in the region from about 59.5 cM to about 67.9 cM on bovine chromosome BTA3.
In a further useful embodiment, the at least one genetic marker is located on the bovine chromosome BTA3 in the region flanked by and including the polymorphic microsatellite markers INRAAOO3 and BMS937.
In a further aspect, the at least one genetic marker is located on the bovine chromosome
BTA3 in the region flanked by and including the polymorphic microsatellite markers
INRAAQOO3 and ILSTS029.
In another advantageous embodiment, the at least one genetic marker is selected from the group consisting of microsatellite markers BM4129, INRAA0O3, BMS2790, ILSTS029,
INRA123, BM220, HUJ246, BMS862, BMS937, BL1048, BMS2095 and BMS1266.
As described in the examples, the at least one genetic marker may be linked to a gene causing the bovine complex vertebral malformation disease. Thus, in one embodiment, the at least one genetic marker is located on bovine chromosome BTA3 in the region flanked by and including the polymorphic microsatellite markers BM4129 and BMS1266 and genetically linked to the CVM disease trait or the CVM gene locus at a lod score of at least 3.0, such as at least 4.0, including at least 5.0, such as at least 6.0, including at least 7.0 such as at least 8.0, including at least 9.0 such as at least 10.0, including at least 11.0, such as at least 12.0.
The specific definition and locus of the above polymorphic microsatellite markers can be , found in the USDA genetic map (Kappes et al., 1997). . 35 It will be appreciated that in order to detect the presence or absence in a bovine subject of a genetic marker associated with CVM, more than one genetic marker may be applied in accordance with the invention. Thus, the at least one marker can be a combination of two or more genetic markers which are shown to be informative whereby the accuracy of the test can be increased.
Accordingly, as further exemplified below, in one useful embodiment, two or more of the - microsatellite markers INRAAOQ3, BMS2790, ILSTS029, INRA 123, BM220, HU3246,
BMS862, BMS937 can be used in combination. . 5
In accordance with the invention, the nucleotide sequences of the primer pairs for ampli- fying the above microsatellite markers are described in Table 4 below.
The comparative maps (Solinas-Toldo et al., 1995) show that most of bovine chromosome
BTA3 corresponds to a part of human chromosome 1 (HSA1). The genetic mapping of the
CVM locus presented herein makes it possible to use the information available about hu- man genes and to concentrate the search for the candidate gene to genes present on human chromosome 1. This will greatly limit the number of candidate genes and facilitate the search for the CVM causative gene.
Genetic markers of the present invention can be made using different methodologies known to those skilled in the art. Thus, it will be understood that with the knowledge presented herein, the nucleotide sequences of the above described polymorphic microsatellite markers of bovine chromosome BTA3 have been identified as being genetically linked to the CVM gene locus, and additional markers may be generated from the known sequences or the indicated location on bovine chromosome BTA3 for use in the method of the present invention.
For example, using the map illustrated in Figure 2, the CVM region of bovine chromosome
BTA3 may be micro-dissected, and fragments cloned into vectors to isolate DNA segments which can be tested for linkage with the CVM gene locus. Alternatively, with the nucleotide sequences provided in Table 4, isolated DNA segments can be obtained from the CVM region by nucleic acid amplification (e.g., polymerase chain reaction) or by nucleotide sequencing of the relevant region of bovine chromosome BTA3 ("chromosome walking").
Additionally, the above described homology between bovine chromosome BTA3 and human chromosome 1 (HSA1) indicates that any gene or expressed sequence tag that is mapped , to this analogous region in human may also map to the CVM region of bovine chromosome
BTA3. Thus, genes or conserved sequences that map on human chromosome HSA1 may be analysed for linkage to the CVM gene locus using routine methods.
Genotyping is based on the analysis of genomic DNA which can be provided by using standard DNA extraction methods as described herein. When the genomic DNA is isolated and purified, nucleic acid amplification (e.g. polymerase chain reaction) can be used to amplify the region of the DNA corresponding to each genetic marker to be used in the analysis for detecting the presence in a bovine subject of a genetic marker associated with : CVM. Accordingly, a diagnostic kit for use in such an embodiment comprises, in a separate packing, at least one oligonucleotide sequence selected from the group consisting of SEQ
ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID
NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID
NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO: 33, SEQ ID NO: 34,
SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37 and SEQ ID NO: 38, and combinations thereof,
Identification of a mutation in the bovine SLC35A3 gene causative and diagnostic for CVYM in cattle
Having established the genomic localisation of the CVM gene delimited by polymorphic microsatellite markers, a search for the identification of the structural gene and the causa- tive mutation herein was performed which can be used as an ultimate genetic marker for
CMV.
The human genome sharing sequence homology to the CVM region, defined as the region between the markers INRAOO3 and ILSTS029, was identified. The marker BMS2790 is located in this interval (Figure 1). Initially, 5 different clones from a bovine BAC library (RPCI-42, constructed and made available by P. de Jonge and co-workers) were identified, each harbouring one of the markers INRA0O3, ISLTS029, or BMS2790. Using sequence information obtained from these BAC clones, a single region on human chromosome 1 which contained a region of homology to the marker-containing BACs was identified using the BLASTN programme on public sequence databases. This region spans about 6 million base pairs and is located in position approx. 107.4-113.5 (Figure 3) (ENSEMBL viewer, The
Sanger Centre).
Isolation and sequencing of the SLC35A3 cDNA
Based on a homology alignment of the SLC35A3 gene between homo sapiens and canis familiaris, 2 oligos (SL1F and SL8R) were designed for amplification of almost the entire ’ cDNA for bovine SLC35A3, including the start codon. PCR was performed on cDNA isolated from heart tissue samples collected from a wildtype animal, a CVM carrier, and an affected ) animal, respectively. To obtain the sequence of the 3’-end of the gene, the resulting PCR fragment was sequenced and a new oligo designed (SL5F). To amplify the 3’ end of
SLC35A3, SL5F was used in combination with an oligo (bSLCBVIR), designed using the published sequence of a partial bovine EST (genbank, dbEST). The cDNA sequence (SEQ
ID NO: 18) and the translated peptide sequence (SEQ ID NO: 17) of bovine SLC35A3 is shown in Figure 4. The protein encoded by bovine SLC35A3 contains 326 amino acids and shares homology to a family of previously known proteins involved in the transport of ’ nucleotide sugars from the cytosol into the Golgi lumen. The alignment depicted in Figure shows the homology to SLC35A3 proteins previously described in human (Ishida et al. ’ 5 1999) and in dog (Guillen et al. 1998).
Detection of a polymorphism in the SLC35A3 gene
To detect potential polymorphisms in the bovine SLC35A3 gene, PCR amplification of the gene was performed using cDNA isolated from heart tissue samples collected from a CVM carrier and an affected animal, respectively. Sequencing of the fragment isolated from the affected animal revealed a sequence identical to the wildtype, except for the affected animal being homozygous for the nucleotide T in nucleotide position 559, compared to the wildtype animal being homozygous for G in the corresponding position (see Figure 4).
Sequencing of the cDNA from an animal being carrier of the CVM-defect showed this animal to be heterozygous having both T and G in position 559.
The exchange of G to T in position 559 affects the sequence of the resulting peptide in changing a valine in position 180 to a phenylalanine (see Figure 4).
Typing the SLC35A3 polymorphism by a DNA sequencing based assay
Figure 6 shows the results obtained from sequencing a PCR fragment amplified from ge- nomic DNA and containing the region {from 544 to 572 of the SLC35A3 cDNA, for num- bering see Figure 4) containing the G/T mutation. The left and right panels show forward and reverse sequencing, respectively. The upper row (marked by -/-) shows the wildtype result, showing a G in the polymorphic position using forward sequencing and a C in the similar position on the other strand using reverse sequencing (marked by asterisks). The lower row +/+ shows the results from an affected calf, showing a T in the polymorphic position using forward sequencing and an A in the similar position on the other strand using reverse sequencing (marked by asterisks). The heterozygote (+/~) is shown in the middle panel and expectedly displays as a mixture of the wildtype and affected signal and ' thus has both a T and a G signal using forward sequencing and an A and a C signal on the other strand.
All calves affected by CVM are homozygous for the T-allele
Genotyping of 39 calves affected by CVM was performed by sequencing of a PCR product amplified from genomic DNA (see Figure 6 and example 6). All of these animals were homozygous for the T-allele, confirming the initial results.
The T-allele is not found in animals unrelated to Bell
Since calves affected by CVM have been reported only in pedigrees containing the widely used bull BELL, it was investigated whether the T-allele was present in animals unrelated to BELL. Taking advantage of the Danish Cattle Database, 496 animals of the Holstein breed without BELL in their pedigree were identified and sampled. Genotyping of these animals was performed by sequencing of a PCR product amplified from genomic DNA (see
Figure 6 and example 6). None of these animals contained the T-allele, suggesting that this allele is found exclusively in the line of animals closely related to BELL.
By sequencing, more than 326 unrelated (at least for the last three generations) animals of 12 different breed were also genotyped. All of these animals were homozygous for the wildtype allele (G-allele) again demonstrating the lack of the CVM-related allele (the T-al- lele) in the general cattle population.
Typing the SLC35A3 polymorphism by an allele-specific PCR assay (AS-PCR)
In order to type the G/T polymorphism efficiently, an allele-specific PCR assay using
BIOLASE Diamond DNA Polymerase from Bioline was developed. This polymerase requires a perfect match of the 3’ end of the primer to the template, and a mismatch at this position will result in no (or very weak) amplification. In this way, it is possible to distin- guish between wildtype, carrier or sick animals by identifying the presence or absence of allele-specific PCR products (Figure 7). The left part of Figure 7 shows the Allele-Specific
PCR products of the coding strand. As expected, wild type animals show amplification with the G-specific primer but not with the T-specific primer. The carriers show amplification of both the G- and T-specific primers, while sick animals only show amplification of the T- specific primer. The right part shows the Allele-Specific PCR products of the non-coding , strand, and as expected, the patterns are the same as the coding strand. Wild type ani- mals are homozygotic C, carriers are heterozygotic C/A, and sick animals are homozygotic . A.
From the above described results of using a positional candidate gene approach, a bovine gene was identified which is homologous to the human gene SLC35A3 encoding 2 UDP-N- acetylglucosamine transporter. Within this gene a G/T polymorphism was identified which alters the amino acid sequence of the protein. All affected calves analysed (39) are homozygous for the T-allele (T/T) and known carriers (108) are all heterozygous for the : polymorphism (G/T). Analysis of more than 500 animals of the Holstein breed, chosen as being unrelated to Bell, failed to identify any animals carrying the T-allele. More than 1500 . 5 animals were analysed having Bell in the pedigree without finding any unaffected animal being homozygous for the T-allele. Furthermore, more than 300 cattle selected from 12 different breeds were analysed without detecting the T-allele in any of these animals.
Taken together, the findings described in the present application demonstrate that the T- allele is present in a single copy in animals which are carriers of CVM and in two copies in animals affected by CVM. Detection of the T-allele in position 559 (numbering from Figure 4} is therefore diagnostic for CVM and ideal for detection of carriers of the CVM defect.
As the G/T polymorphism has been identified as being causative for CMV, any genetic markers closely coupled to this polymorphism may be diagnostic for CMV in a bovine population. Accordingly, the present invention describes a method to identify bovine subjects either affected by CMV or carriers of CMV by determining the presence of the G/T polymorphism at position 559 of the bovine SLC35A3 gene, either indirectly by analysing any genetic markers, such as microsatellites described herein, coupled to the bovine
SLC35A3 gene or directly by analysing the sequence of the bovine SLC35A3 gene, e.g. as described above and in further details in the examples.
Within the scope of the present invention is therefore a method for detecting and/or quan- tifying the presence of a genetic marker associated with bovine CVM in a bovine subject in order to be able to identify the CMV affected bovine subjects or carriers of CMV. The steps of the method comprises: a) providing a bovine genetic material, and b) detecting, in said genetic material, the presence or absence of at least one genetic marker that is linked to a bovine complex vertebral malformation disease trait.
The at least one genetic marker is linked to a gene causing bovine CMV disease, said gene being identified herein to be the bovine SLC35A3 gene which encodes the bovine SLC35A3 ) protein comprising an amino acid sequence as shown in SEQ ID NO: 17. . 35 More specifically, the present invention relates to a method for detecting bovine CMV, wherein the genetic marker is a single nucleotide polymorphism at a position equivalent {o nucleotide 559 of SEQ ID NO:18, said single nuclectide polymorphism being a G/T poly- morphism.
« 12
The present application furthermore describes an efficient assay for the genotyping of the present polymorphism using allele-specific PCR. This is but one of a battery of methods for : the typing of SNPs, other methods which could be employed include, but are not limited to, mini-sequencing, primer-extension, pyro-sequencing, PCR-RFLP, allele-specific rolling . 5 circle-amplification, primer-extension followed by MALDI-TOF mass-spectrometry as well as a range of other enzymatic and hybridisation-based methods.
A phenotype resembling CVM has been demonstrated to exist in mice mutated in the gene lunatic fringe (Evrad et al., 1998). Similar to calves affected by CVM, mice homozygous for a null mutation in funatic fringe exhibit an altered somite segmentation and patterning, having a shortened body axis, vertebral- and rib-fusions and incompletely formed vertebrae (Evrad et al., 1998). Fringe seems to participate in the definition of boundary formation and somite patterning by modulating the activity of notch receptors (Klein and
Arias, 1998; Moloney et al., 2000, Briickner et al., 2000). The Notch-modulating activity seems to be mediated by an N-acetylglucosaminyl-transferase activity of Fringe, which in
Golgi initiates the elongation of O-linked fucose residues attached to EGF-like sequence repeats of Notch (Moloney et al., 2000; Brickner et ai., 2000).
Furthermore, as the bavine SLC35A3 gene is homologous to the human SLC35A3 gene, it is, with the information given herein, obvious to analyse the coding sequence of the human SLC35A3 gene for causative and diagnostic mutations when studying human de- velopmental defects, especially involving somite-segmentation and patterning.
The effect of a mutation in the Golgi-located N-acetylglucosaminyl! transporter (SL.C35A3) affecting transport of N-acetylglucosamine from the cytosol into the lumen of Golgi would be expected to deprive the Fringe family of proteins for their substrate. This would affect the ability of Fringe to modulate Notch activity and thereby cause a segmentation defect like CVM. It therefore seems very plausible that the mutation in SLC35A3, apart from being diagnostic for CVM, is also the mutation causing this widespread genetic defect.
The invention is described in further details in the following examples:
” 13
Example 1
Genetic mapping of Complex Vertebral Malformation {CvM)
This example illustrates the localisation of the CVM gene locus to bovine chromosome
BTA3. Additionally, this embodiment describes the identification of markers linked to the
CVM gene focus, and thus the characterisation of the CVM region of bovine chromosome
BTA3.
In order to map the locus responsible for CVM, samples were obtained from animals par- ticipating in a breeding study. Briefly, approx. 300 cows and heifers descending from the bull 7 Burma and inseminated with semen from the bull KOL Nixon were selected for the breeding study. Thirteen affected calves were selected on the basis of the post mortem examination, as described in Agerholm et al., 2000. These 13 calves as well as their parents, in total 28 animals, were used in the initial genome scan. The calves were sepa- rated by 4 generations to their common ancestor, the purebred bull Carlin-M Ivanhoe Bell.
The genome scan was conducted, covering all 29 autosomes, using a battery of micro- satellite markers picked from the USDA genome map (Kappes et al., 1997). Markers were selected with pair-wise distances between 10 and 20 cM. In areas of doubt due to low marker informativity, new markers were included and typed. A total of 194 markers were used, PCR reactions were performed in duplexes in a volume of 5 pl in an ABI 877 PCR robot (Applied Biosystems), containing 12 ng of genomic DNA, 1x PCR buffer, 0.4 U
AmpliTaq Gold (Applied Biosystems), 20 pmol of each primer and 2.0 mM MgCl,. All markers were run at the same touchdown PCR conditions: incubation at 94°C for 12 minutes to activate the enzyme, 35 cycles at 949C, 30 sec; Ta, 45 sec; 72°C, 20 sec, ending with a final extension at 72°C for 10 min. The first ten cycles Ta decreased from 670C to 58°C, one degree for each cycle, and the remaining 25 cycles Ta were fixed at 580C. PCR products were pooled and 5 to 9 different markers were run in each lane on an
ABI 377 (Applied Biosystems), and gels were analysed with the accompanying software.
Alleles were assigned with the Genotyper programme (Version 2.1, Applied Biosystems).
For three markers, two-point lod scores were calculated using the MLINK programme of the LINKAGE package (Lathrop et al., 1985). Due to the pedigree structure (Figure 1) with multiple inbreeding loops, the pedigree was divided into thirteen small families, one for each affected calf including the Sire (KOL Nixon), the dam and the maternal grandsire (7
Burma). The disease was assumed to be recessively inherited with a complete penetrance of the genotype.
v 14
Significant linkage was found for all three markers. The highest lod score (Z) was observed . with BMS2790 and ILSTS029 with Z=10.35 at 6=0. Furthermore, the nearby marker
INRAOO3 was also significantly linked to the CVM locus (Table 3). . 5
TABLE 3
Two point lod scores (Z) and recombination fractions (8) from the linkage analysis of the CvM locus and bovine chromosome 3 markers.
Were Potaniptiation fadien Led seo (8) ‘BMS2790 0.00 10.35
INRAOO3 0.03 6.44
ILSTS029 0.00 10.35
The above results locate the CVM locus to BTA3 (Figure 2) according to the USDA genetic map (Kappes et al., 1997). e Eleven calves were homozygous for the interval defined by INRA0O03, BMS2790,
ILSTS029, BMS862 and HUJ246, while BMS2790 and ILSTS029 alone were homo- zygous in all thirteen calves as depicted in Figure 1. It was possible to construct haplotypes of these markers, allowing us to deduce the most likely CVM haplotype (Figure 1). The haplotypes are defined by the size of the marker alleles which are numbered from 1 to N where 1 defines the shortest allele of the amplified marker and
N defines the longest allele. The actual length of the alleles associated with CVM in Bell is as follows:
INRAOO3 (allele no. 3): 176 base pairs
BMS2790 (allele no. 3): 118 base pairs
ILSTSO029 (allele no. 2): 164 base pairs
BMS862 (allele no. 1): 130 base pairs
HUJ246 (allele no. 3): 262 base pairs
The actual length of the alleles will depend upon the primers used to amplify the marker, and the fragment lengths shown above is based on using the primers described in Table 4.
Furthermore, seventeen additional affected calves sampled as part of the Danish surveil- lance programme for genetic defects were included in the study. All affected animals had the pure-bred bull Bell as a common ancestor. DNA was extracted from blood samples or semen using standard procedures.
P
15
The 17 calves and their mothers were genotyped with the 8 markers INRAQO3, BMS2790,
ILSTS029, BM220, INRA123, BMS862, BMS937, and HUJ246 spanning the region on BTA3 - from approximately 59.5 cM to 67.9 cM, and since the CVM gene in the additional 17 calves, like in the initial breeding study, was assumed to originate from the common . 5 ancestor bull Bell, a similar region of identity by descent (IBD) was expected to exist in all affected calves. This also turned out to be the case: in 17 out of 17 calves the chromo- some segment defined by INRAOO3 and BMS2790 was homozygous, sharing the same alleles as the animals from the breeding study. In two of the nineteen animals, heterozy- gosity was observed in the ILSTS029 and BMS862 locus explained by single recombination events between BMS2790 and ILSTS029. Thus, based on the combined genotyping results, we have found that the CVM genetic defect is most likely located in an interval of less than 6 cM, flanked by the markers INRA0O3 and ILSTS029 as illustrated in Figure 2 and denoted "CVM region".
The sequences of the primers for the applied 8 markers INRA0O3, BMS2790, ILSTS029,
BM220, INRA123, BMS862, BMS937, and HUJ246, are depicted in Table 4 below.
TABLE 4 —— — = R: CTA AGA GTC GAA GGT GTG ACT AGG {SEQ ID NO:2 = R: AAA GAG TCG GAC ATT ACT GAG C SEQ ID NO:4 = R: TGG ATT TAG ACC AGG GTT GG SEQ ID NO:6 wesiz EGS Gmcrc caer ic |S iohos
R: AGA GAG CAA CTC CAC TGT GC SEQ ID NO:8 = R: TAG GTA CCA TAG CCT AGC CAA G SEQ ID NO:10 wee CCAS eee rote [Sean
R: TGC CAT GTA GTA GCT GTG TGC SEQ ID NO:12 = R: ATG GAA AAA TAA GAT GTG GTA TGT |SEQ ID NO:14 _ R: CAT TAT CCC CTG TCA CAC ACC SEQ ID NO:16 rl 16
Example 2
Diagnostic test to identify CVM carriers:
A diagnostic test to determine bovine carriers of CVM was established by determining whether descendants from Bell were carriers of the disease-associated haplotype.
The test was based upon the 8 microsatellite markers INRA0OO3, BMS2790, ILSTS029,
BM220, INRA123, BMS862, BMS937 and HUJ246, and relied upon the recognition of the disease specific alleles or haplotype (see Figure 1) in animals descending from Bell.
Animals were thus determined to be carriers if they had inherited the disease-associated alleles in the region defined by the markers INRA0O3, BMS2790, ILSTS029, and BM220 from Bell or from animals descending from Beli. If the animals had not inherited the dis- ease-associated haplotype from Bell or from animals descending from Bell, they were determined to be non-carriers. In cases where the Bell haplotype had been split by re- combination, the animals were designated as indeterminable. The four additional markers were only used when the information content in the test markers was decreased due to inability to distinguish between maternal and paternal inheritance.
Like all diagnostic genetic tests based upon linked DNA markers, the CVM test suffers from the drawback that a double recombination event (one event at each side of the causative gene, between the gene and the flanking markers) cannot be detected. In the present case, this event will be extremely rare due to the tight linkage between the markers and the CVYM gene, and the reliability of the test is estimated to be higher than 99%.
Example 3
Tissue Dissection and RNA isolation and cDNA synthesis:
Roughly 5 grams of heart tissue were dissected from dead-born calves within 3 hours of delivery, immediately frozen in liquid nitrogen and stored at -80°C. 250 mg of tissue was used for RNA isolation. RNA was isolated using the RNA Isolation Kit from Stratagene (cat. , 200345). - cDNA was synthesised by mixing 2.5 pg of total RNA with 1 pl of oligo (dT)42.18 (500 pg/ml), 1 pl of 10 mM dNTP mix and H,O to give a final volume of 12 pl. The resulting mixture was heated at 65°C for 5 min, chilled on ice and spun briefly, Following the addition of 4 ul of 5 x first-strand buffer, 2 pul of 0.1 M DTT and 1 ul of H,0, the contents were mixed and incubated at 42°C for 2 min, after which 1 pl (200 U) of Superscript II
(GibcoBRL® Lifetechnologies) was added and the incubation allowed to continue at 42°C for 1.5 hours. The reaction was inactivated at 70°C for 15 min. To remove RNA, the cDNA . was incubated at 37°C for 20 min with 1 U RNase H (Roche Molecular Biochemicals). ) 5 Example 4
Sequencing of SLC35A3:
Based on a homology alignment of the SLC35A3 gene between homo sapiens and canis familiaris, 2 oligos (SL1F and SL8R) were designed for amplification of almost the entire cDNA for bovine SLC35A3, including the start codon. To obtain the 3’ end of the gene, the resulting PCR fragment was sequenced and a new oligo designed (SL5F). To amplify the 3’ end of SLC35A3, SL5F was used in combination with an oligo (bSLCBVIR), based on a published sequence of a bovine EST.
The same PCR conditions were applied for both primer sets.
The PCR reactions were performed in a GeneAmp® PCR System 9700 (Applied Bio- systems) in a final volume of 10 yl consisting of 1 pt of 10xNH, reaction buffer, 0.5 ul of 50 mM MgCl, 0.8 pl of dNTPs (2.5 mM of each), 5.65 ul of H,0, 1 ul of forward and reverse primer (5 pmol of each) and 0.05 ul of 5 U/ul BIOTAQ DNA polymerase (Bioline).
The touchdown PCR reaction consisted of an initial heat activation step at 95°C for 2 min followed by 10 cycles of denaturation for 30 sec at 95°C, annealing at 62°C for 30 sec (0.5°C decrements), and elongation for 20 sec at 72°C, plus an additional 30 cycles with a denaturation step for 30 sec at 95°C, an annealing temperature of 57°C for 30 sec and an elongation step at 72°C for 30 sec.
The following primers were used to amplify the complete SLC35A3 cDNA:
SLiF: 5'-GGA GGC AAA TGA AGA TAA AAC-3’' (SEQ ID NO: 19)
SL8R: 5'-CTA TGC TTT AGT GGG ATT3-' (SEQ ID NO: 20) : SL5F: 5’-GAG TTG CTT TTG TAC AGT GG-3' (SEQ ID NO: 21) bSLCBVIR: 5'-ACT GGC TAC TAT CTA GCA CAG GA-3’ (SEQ ID NO: 22)
The complete cDNA sequence was obtained by applying these primers in four separate cycle sequencing reactions using purified PCR products as the template. The PCR products were purified using SPIN-X® (Corning Incorporated) from a 0.8% Seakem agarose gel.
18
Cycle sequencing reactions were carried out in a GeneAmp® PCR System 9700 (Applied : Biosystems) and included an initial step at 96°C for 2 min followed by 99 cycles of 96°C for sec, 55°C for 5 sec and 60°C for 4 min. Sequencing products were precipitated with two v - 5 volumes of ethanol and 1/10 volume of 3 M NaAc (pH 5.5), washed with 70% ethanol, resuspended in 5 pi of loading buffer and run on 4% acrylamide seguencing gels using an
ABI377 automatic sequencer.
The cDNA sequence of the bovine SLC35A3 is shown in Figure 4 (SEQ ID NO: 18). 10
Example 5
Identification and isolation of BACs containing microsatellite markers
Filter hybridisation:
The filters were pre-hybridised in hybridisation solution (6xSSC {52.6 g of NaCl, 26.46 g of sodium citrate per litre), 5x Denhardt (2 g of ficoll (type 400, Pharmacia), 5 g of polyvinylpyrrolidone, 5 g of bovine serum albumin (Fraction V, Sigma), 0.5% SDS and 50 pg/ml SS-DNA) at 65°C for 3 hours with rotation. 100 pl of 5’-end labelled oligonucleotide was then incubated with the filters for 16 hours at 65°C. For end labelling, 5 pmol of oligonucleotide was combined with 5 pl (50 pCi) of gamma-32P-ATP (specific activity > 5000 Ci/mmole), 2 pl of 10x kinase buffer, 11 yl of H,O and 1 pl (10 U) of T4 polynucleotide kinase (New England Biolabs Inc.), and the mix was incubated at 37°C for 1.5 hours followed by 5 min of boiling to heat inactivate the enzyme. The labelled probe was NaAc/ethanol precipitated using standard procedures, and after a wash in 70% ethanol, the probe was redissolved in 100 pl of H,0. Following hybridisation the filters were washed once with wash solution I (2xSSC, 0.2% SDS) and twice at 65°C with wash solution II (0.1xSSC, 0.5% SDS), and exposed to Kodak BIOMAX™ MS film for 2 days at - 80°C.
The following 5-end labelled oligonucleotides were used to identify ILSTS029 and INRAOO3 positive BAC clones:
ILSTS029 oligo: 5'-CAC ACC GCT GTA CAG GAA AAA GTG TGC CAA CCC TGG TCT AAA . TCC AAA ATC CAT TAT CTT CCA AGT ACA T-3' (SEQ ID NO: 23)
INRAOO3 oligo: 5'-CGT CCC CTA TGC GCT TAC TAC ATA CAC TCA AAT GGA AAT GGG
AAA ACT GGA GGT GTG TGA GCC CCA TTT A-3’ (SEQ ID NO: 24)
19
PCR screening of the bovine BAC library:
BAC pools were prepared from the BAC library and screened by PCR. The PCR reactions . were performed in a GeneAmp® PCR System 9700 (Applied Biosystems) in a final volume of 10 pl consisting of 1 pl of 10xNH, reaction buffer, 0.5 ul of 50 mM MgCl,, 0.8 ul of dNTPs (2.5 mM of each), 5.65 pl of H,0, 1 ul of forward and reverse primer (5 pmol of each) and 0.05 pl of 5 U/ul BIOTAQ DNA polymerase (Bioline).
The following primers were used to identify BMS2790 containing BAC clones by PCR:
BMS2790F: 5'-AAG ACA AGG ACT TTC AGC CC-3' (SEQ ID NO: 25)
BMS2790R: 5-AAA GAG TCG GAC ATT ACT GAG C-3’ (SEQ ID NO: 26)
The touchdown PCR reaction consisted of an initial heat activation step at 95°C for 2 min followed by 10 cycles of denaturation for 30 sec at 95°C, annealing at 70°C for 30 sec (0.5°C decrements), and elongation for 20 sec at 72°C, plus an additional 30 cycles with a denaturation step at 95°C for 30 sec, annealing at 65°C for 30 sec and elongation at 72°C for 20 sec.
BAC DNA isolation and sequencing:
BAC DNA was prepared according to Qiagens Large Construct Kit, and approximately 1 ug of BAC DNA was used as the template for cycle sequencing performed with the BigDye™
Terminator Cycle Sequencing Kit (PE Applied Biosystems). The cycle sequencing reactions were performed in a final volume of 6 pl containing 1 pl of Big Dye™ Terminator mix, 1 pl of primer (5 pmol), 1 pl of reaction buffer and 2 p! of H,O. Cycle sequencing reactions were carried out in a GeneAmp® PCR System 9700 (Applied Biosystems) and included an initial step at 96°C for 2 min followed by 130 cycles of 96°C for 10 sec, 55°C for 5 sec and 60°C for 4 min. Sequencing products were precipitated with two volumes of ethanol and 1/10 volume of 3 M NaAc (pH 5.5), washed with 70% ethanol, resuspended in 2 pl of loading buffer and run on 4% acrylamide sequencing gels using an ABI377 automatic sequencer.
Sequencing primers: ‘ T7: 5-TTA TAC GAC TCA CTA TAG GG-3’ (SEQ ID NO: 27)
SP6: 5-ATT TAG GTG ACA CTA TAG-3' (SEQ ID NO: 28) . 35 INRAOO3F: 5'-CTG GAG GTG TGT GAG CCC CAT TTA-3’ (SEQ ID NO: 29)
INRAQOO3R: 5°-CTA AGA GTC GAA GGT GTG ACT AGG-3’ (SEQ ID NO: 30)
20
Example 6
Determination of CVYM status by sequencing:
PCR reactions (2 pl of purified template/sample genomic DNA, 2 pl of 10xPCR buffer, 2 pl of 25 mM MgCl,, 3.3 pl of 0.2 mM of each dNTP (Ultrapure dNTP, 27-2033-01; Amersham
Pharmacia Biotech), 6 pmol of primer (forward: CBFEX1, 5'-GGC CCT CAG ATT CTC-3' (SEQ ID NO: 31); reverse: CBTEXR, 5'-GTT GAA TGT TTC TTA-3') (SEQ ID NO: 32), 0.165 U Tag polymerase (Biotag, M95801B; Bioline), dH,0 ad total volume) were performed oil-free in 96-well plates using a Primus HT (MWG Biotech AG). Cycling conditions: 95°C 120 sec, 35x [95°C 60 sec, 60°C 30 sec, 72°C 110 sec]. Post-reaction clean-up was done by gel filtration (Millipore Filtration System) with Sephadex G-50
Superfine (17-0041-01, Amersham Pharmacia Biotech) carried out according to the manufacturer's recommendation, using 50 pl of dH,0 for final sample elution. Forward and reverse sequencing reactions were performed with the same primers as used for the generation of the PCR product (2 pl of PCR product, 8 pl of Sequencing Mix, 0.6 pl of 6 pmol Primer (see above), dH,0 ad 20 pl; DYEnamic ET Dye Terminator Cycle Sequencing
Kit (US81095). After thermocycling (30x [95°C 20 sec, 55°C 15 sec, 60°C 70 sec]) samples were cleaned by gel filtration essentially as described above and analysed on a
MegaBACE1000 (Amersham Pharmacia Biotech) using LPA long-read matrix and the following sequencing conditions: 90 sec injection at 3 kV and 35 min run time at 9 kV.
Example 7
Allele-specific PCR assay:
Primers were designed from the cDNA sequence and the four allele-specific primers were designed to have the 3’ base at the position of the mutation.
Primer sequences:
T_fwd: 5’-CAG TGG CCC TCA GAT TCT CAA GAG CTT AAT TCT AAG GAA CTT TCA
GCT GGC TCA CAA TTT GTA GGT CTC ATG GCA T-3' (SEQ ID NO: 33)
G_fwd: 5’-CAC AAT TTG TAG GTC TCA TGG CAG-3’ (SEQ ID NO: 34) i A_rev: 5-GCC ACT GGA AAA ACA TGC TGT GAG AAA-3’ (SEQ ID NO: 35)
C_rev_link*: 5'-aat gct act act att agt aga att gat gcc acc ttt tca get cgc gcc cca aat gaa aat ata gct aaa cag gtt att gac cat ttg cga aat gta tct aat ggt caa act ttt ttC TGG AAA AAC ATG CTG TGA GAA C -3' (SEQ ID NO: 36)
. 21
Fwd: 5’-GGC CCT CAG ATT CTC AAG AGC-3’ (SEQ ID NO: 37)
Rev: 5’-CGA TGA AAA AGG AAC CAA AAG GG-3’ (SEQ ID NO: 38) : 5
The C_rev_link primer contains a linker sequence from the M13 phage (shown in lower case letters). This linker was added to obtain a longer PCR product in order to be able to multiplex the C- and A-primers in one PCR reaction. The 3’ base at the position of the mutation is shown in bold. The C- and G-primers are specific for the wildtype allele, while the T- and A-specific primers are specific for the mutation.
Primer pairs:
C- and A-specific multiplex: Fwd + A_rev + C_rev_link (lower strand)
T-specific reaction: T_fwd + Rev (upper strand)
G-specific reaction: G_fwd + Rev (upper strand)
AS-PCR conditions:
Each PCR reaction was carried out in a 10 ul volume containing 20-100 ng of genomic
DNA, 0.025 units/pl of BIOLASE Diamond DNA polymerase, 0.75 mM dNTPs, 3 mM MgCl, 0.25 pmol/pl primer (0.125 pmol/ul of the two reverse primers in the multiplex) in 1 x NH4 buffer (Bioline). PCR was carried out in a GeneAmp® PCR System 9700 (PE Applied
Biosystems) under the following conditions: 95°C for 4 min, 35 cycles of 94°C for 30 s, 62°C (56°C for the T- and G-reaction) at ramp 80% for 30 s, and 72°C for 30 s followed by a final extension at 72°C for 7 min and storage at 4°C. PCR was followed by electrophoresis in a 2% agarose gel at 200 V for 30 min.
The results of the allele-specific PCR analysis of two wildtype, two carriers, and two sick animals are shown in Figure 7.
> a WO 02/40709 PCT/DK01/00756 22
Figure legends . Figure 1 shows the pedigree used to locate the bovine complex vertebral malformation (CVM) locus and haplotypes of five microsatellite markers on bovine chromosome 3. The . most likely CVM haplotypes are in bold. Filled black squares represent affected calves.
Double lines between the sire and the dams indicate inbreeding loop. N refers to the number of animals. Genotypes of the thirteen different dams are for simplicity reasons not shown.
Figure 2 shows the genetic map of bovine chromosome 3. Numbers on the sides refer to the genetic distances given in centiMorgan (cM) along the chromosome. The most likely location of the bovihe complex vertebral malformation (CVM) locus is indicated.
Figure 3 shows the relative distance in cM between the 3 microsatellite markers ILSTS029,
BMS2790 and INRAOO3 (shown on the line denoted Contig markers on bovine Chr. 3) on the bovine chromosome 3 as depicted by the U.S. Meat Animal Research Center (Kappes et al. 1997). BACs containing these 3 markers were isolated either by hybridisation to high density replica filters (ILSTS029 and INRAOQ3), or by PCR screening of the RPCI-42 bovine
BAC library (BMS2790). The identified BACs are shown in black bars and annotated by plate number/well number. These BACs were subjected to end-sequencing using SP6 and
T7 primers or to sequencing using primers extending from the microsatellite. The resulting sequences were blasted against the human chromosome 1 using the Ensemble Server at the Sanger Centre. The accession numbers from the blast search are shown as numbers under the human chromosome 1 and the relative distance between the hits is given in MB,
Selected genes in the region are shown in boxes.
Figure 4 shows the cDNA sequence and translation of the SLC35A3 gene (SEQ ID NO: 18) and the encoded amino acid sequence (SEQ ID NO: 17). The polymorphic nucleotide in position 559 and the affected valine-180 is indicated in bold.
Figure 5 shows a comparison of the deduced amino acid sequence of cow SLC35A3 with human (AB021981) (Ishida et al. 1999) and dog (AF057365) (Guillen et al. 1998) sequences. Dots indicate residues that match the Bos Taurus sequence. Dashes indicate gaps that have been introduced to optimise the alignment.
Figure 6 shows the results obtained from sequencing the region (from nucleotide 544 to 572 of SLC35A3, see Figure 4) showing the G/T polymorphism in position 559 in determi- nation of CVM status by sequencing. The left and right panels show forward and reverse ’ sequencing, respectively. The upper row (-/-) shows the sequencing of a wildtype animal, the middle row shows the sequencing of a carrier (heterozygote), and the lower row shows the sequencing of an affected animal.
Figure 7 is a picture showing the Allele-Specific PCR products from two wildtype, two carriers, and two sick animals.
Annotations: WT: wildtype, C: carrier, S: sick, neg: . negative control, M: marker (size ladder). Arrows show the allele-specific PCR products: C: 220 bp, A: 98 bp, T: 340 bp, and G: 288 bp.
References - 1. Agerholm JS, Bendixen, C., Andersen O., Arnbjerg, J. (2000) LK meddelelser October 2000. . 2. Barendse W, Vaiman D, Kemp SJ, Sugimoto Y, Armitage SM, Williams JL, Sun HS,
Eggen A, Agaba M, Aleyasin SA, Band M, Bishop MD, Buitkamp J, Byrne K, Collins F,
Cooper L, Coppettiers W, Denys B, Drinkwater RD, Easterday K, Elduque C, Ennis S,
Erhardt G, Li L, Lil L (1997) A medium-density genetic linkage map of the bovine ge- nome. Mamm Genome 8, 21-28. 3. Briickner, K., Perez, L., Clausen, H., & Cohen, S., (2000) Glycosyltransferase activity of
Fringe modulates Notch-Delta interactions Nature 406, pp. 411-415. 4, Evrad, Y. A., Lun, Y., Aulehla, A,. Gan, L., & Johnson, R. L. (1998) Lunatic fringe is an essential mediator of somite segmentation and patterning. Nature 394, pp. 377-381. 5. Guillen, E., Abeijon, C., & Hirschberg, C. B. (1998) Mammalian Golgi apparatus UDP-N- acetylglucosamine transporter: Molecular cloning by phenotypic correction of a yeast mutant. Proc. Natl. Acad. Sci.USA. 95, pp. 7888-7892. 6. Ishida, N., Yoshioka, S., Chiba, Y., Takeuchi, M., & Kawakita, M. (1999) Molecular cloning and functional expression of the human golgi UDP-N-acetylglucosamine transporter. J. Biochem. 126, pp. 68-77. 7. Kappes SM, Keele JW, Stone RT, McGraw RA, Sonstegard TS, Smith TP, Lopez-Corrales
NL, Beattie CW (1997) A second-generation linkage map of the bovine genome.
Genome Res 7, 235-249. 8. Klein, T., & Arias, M. (1998) Interactions among Delta, Serrate and Fringe modulate
Notch activity during drosophila wing development. Development 125, pp. 2951-2962. 9. Lathrop GM, Lalouel JM, Julier C, Ott 3 (1985) Multilocus linkage analysis in humans: detection of linkage and estimation of recombination. Am J Hum Genet 37, 482-498 10. Moloney, D.J., Panin, V. M., Johnston, S. H., Chen, J., Shao, L., Wilson, Y., Stanley, P.,
Irvine, K. D., Haltiwanger, R. S., & Vogt, T. F. (2000) Fringe is a glycosyltransferase that modifies Notch. Nature 406, pp 369-375. 11. Solinas-Toldo S, Lengauer C, Fries R (1995) Comparative genome map of human and cattle Genomics 27, 489-496.
Claims (32)
1. A method for detecting bovine complex vertebral formation (CVM) in a bovine subject, wherein the presence of at least one genetic marker located on bovine chromosome BTA3 in the region flanked by and including the polymorphic microsatellite markers BM4129 and BMS1266 associated with bovine complex vertebral malformation (CVM) is identified, said method comprising a) providing a bovine genetic material, and b) detecting, in said genetic material, the presence or absence of at least one genetic marker that is linked to a bovine complex vertebral malformation disease trait.
2. A method according to claim 1, wherein the at least one genetic marker is located in the region from about 59.5 cM to about 67.9 cM.
3. A method according to claim 2, wherein the at least one genetic marker is located in the region flanked by and including the polymorphic microsatellite markers INRAAOO3 and BMS937.
4, A method according to claim 3, wherein the at least one genetic marker is located in the region flanked by and including the polymorphic microsatellite markers INRAAOO3 and ILSTS029.
5. A method according to claim 1, wherein the at least one genetic marker is the microsatellite marker INRAAQQ3.
6. A method according to claim 1, wherein the at least one genetic marker is the microsatellite marker BMS2790.
7. A method according to claim 1, wherein the at least one genetic marker is the microsatellite marker ILSTS029.
8. A method according to claim 1, wherein the at least one genetic marker is the microsatellite marker INRA123.
9. A method according to claim 1, wherein the at least one genetic marker is the microsatellite marker BM220. Amended Sheet 10 August 2004
10. A method according to claim 1, wherein the at least one genetic marker is the microsatellite marker HUJ246.
11. A method according to claim 1, wherein the at least one genetic marker is the microsateliite marker BMS862.
12. A method according to claim , wherein wherein the at least one genetic marker is the microsatellite marker BMS937.
13. A method according to claim 1, wherein the at least one genetic marker is linked to a gene causing bovine complex vertebral malformation disease.
14. A method according to claim 13, wherein the gene causing bovine complex vertebral malformation disease is the bovine SLC35A3 gene.
15. A method according to claim 14, wherein the bovine SLC35A3 gene encodes the bovine SLC35A3 protein comprising an amino acid sequence as shown in SEQ ID NO: 17.
16. A method according to claim 15, wherein the bovine SI.C35A3 protein is encoded by a cDNA sequence comprising the nucleotide sequence of SEQ ID NO:18.
17. A method according to claim 16, wherein the genetic marker is a single nucleotide polymorphism at a position equivalent to nucleotide 559 of SEQ ID NO:18.
18. A method according to claim 17, wherein the single nucleotide polymorphism is a G/T polymorphism.
19. A method according to claim 18, wherein the detection of the G/T polymorphism is performed by a technique selected from the group consisting of allele-specific PCR, mini- sequencing, primer-extension, pyro-sequencing, PCR-RFLP, allele-specific rolling circle- amplification and primer-extension followed by MALDI-TOF mass-spectrometry.
20. A method according to claim 1, wherein said at least one genetic marker is genetically linked to a gene or disease trait causing bovine complex vertebral malformation disease at a lod score of at least 3.0 Amended Sheet 10 August 2004
21. A method according to claim 1, wherein the at least one marker is a combination of genetic markers.
22. A method according to claim 5, wherein the primer pair for amplifying the microsatellite marker INRAAOO3 is SEQ ID NO:1 and SEQ ID NO:2.
23. A method according to claim 6, wherein the primer pair for amplifying the microsatellite marker BMS2790 is SEQ ID NO:3 and SEQ ID NO:4.
24. A method according to claim 7, wherein the primer pair for amplifying the microsatellite marker ILSTS029 is SEQ ID NO:5 and SEQ ID NO:6.
25. A method according to claim 8, wherein the primer pair for amplifying the microsatellite marker INRA123 is SEQ ID NO:7 and SEQ ID NO:8.
26. A method according to claim 9, wherein the primer pair for amplifying the microsatellite marker BM220 is SEQ ID NO:9 and SEQ ID NO:10.
27. A method according to claim 10, wherein the primer pair for amplifying the microsatellite marker HUJ246 is SEQ ID NO:11 and SEQ ID NO:12.
28. A method according to claim 11, wherein the primer pair for amplifying the microsatellite marker BMS862 is SEQ ID NO:13 and SEQ ID NO:14.
29. A method according to claim 12, wherein the primer pair for amplifying the microsatellite marker BMS937 is SEQ ID NO:15 and SEQ ID NO: 16.
30. A diagnostic kit for use in detecting the presence in a bovine subject of at least one genetic marker associated with bovine complex vertebral malformation (CVM), comprising at least one oligonucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37 and SEQ ID NO:38, and combinations thereof. Amended Sheet 10 August 2004
31. A method according to claim 1, substantially as herein described with reference to any of the illustrative examples.
32. A kit according to claim 30, substantially as herein described with reference to any of the illustrative examples. Amended Sheet 10 August 2004
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200001717 | 2000-11-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200304404B true ZA200304404B (en) | 2004-06-23 |
Family
ID=34072366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200304404A ZA200304404B (en) | 2000-11-16 | 2003-06-05 | Genetic test for the identification of carriers of complex vertebral malformations in cattle. |
Country Status (1)
Country | Link |
---|---|
ZA (1) | ZA200304404B (en) |
-
2003
- 2003-06-05 ZA ZA200304404A patent/ZA200304404B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8715925B2 (en) | Genetic test for the identification of carriers of complex vertebral malformations in cattle | |
US20080305967A1 (en) | Genetic Markers Associated with Endometriosis and Use Thereof | |
US8206911B2 (en) | Identification of the gene and mutation responsible for progressive rod-cone degeneration in dog and a method for testing same | |
EP2310528B1 (en) | A genetic marker test for brachyspina and fertility in cattle | |
AU2002223498A1 (en) | Genetic test for the identification of carriers of complex vertebral malformations in cattle | |
EP2069531B1 (en) | Qtls for mastitis resistance in cattle | |
EP2707497B1 (en) | Detecting the brachyspina mutation | |
ZA200304404B (en) | Genetic test for the identification of carriers of complex vertebral malformations in cattle. | |
US20090148844A1 (en) | Dna marker for meat tenderness in cattle | |
US20030232365A1 (en) | BDNF polymorphisms and association with bipolar disorder | |
EP2149611A1 (en) | A genetic marker test for brachyspina and fertility in cattle |